@article{101920,
  keywords = {Trypanosoma cruzi, Vaccine development, Adjuvant, Murine model, Immunoprophylaxis},
  author = {Santos GSD and Fonseca BDR and Dall’Agno L and Dellagostin OA and Borsuk S},
  title = {Vaccines against Chagas’ disease: a synthetized up-to-date review},
  abstract = {<jats:p>Chagas’ disease (CD) is an infectious disease attacking an estimated 8 million people, mainly in rural areas of Latin America countries. CD has no effective treatment, evidencing the vaccination schedule as the best control strategy. Although some medicaments are available, none of them provides a solution for the infection nor are capable of inducing protection. They also have questionable safety levels and side effects. In light of this, several experimental vaccines are in development in order to improve safety, reproducibility, and protective immune response against the etiologic agent of CD, Trypanosoma cruzi. In this review, we discuss aspects as antigen, adjuvant, routes of administration, protection level, animal models, and economic impact in CD vaccine development, as well the challenges and future perspectives.</jats:p>},
  year = {2025},
  journal = {REVISTA DELOS},
  volume = {18},
  pages = {25},
  publisher = {Brazilian Journals},
  issn = {1988-5245, 1988-5245},
  url = {https://ojs.revistadelos.com/ojs/index.php/delos/article/download/3955/2246},
  doi = {10.55905/rdelosv18.n64-030},
  language = {ENG},
}